Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Net Cash Flow: 2014-2024

Historic Net Cash Flow for Axsome Therapeutics (AXSM) over the last 11 years, with Dec 2024 value amounting to -$70.8 million.

  • Axsome Therapeutics' Net Cash Flow rose 90.48% to $22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year increase of 97.68%. This contributed to the annual value of -$70.8 million for FY2024, which is 138.22% down from last year.
  • Latest data reveals that Axsome Therapeutics reported Net Cash Flow of -$70.8 million as of FY2024, which was down 138.22% from $185.4 million recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Net Cash Flow registered a high of $185.4 million during FY2023, and its lowest value of -$97.4 million during FY2021.
  • Moreover, its 3-year median value for Net Cash Flow was $114.4 million (2022), whereas its average is $76.3 million.
  • As far as peak fluctuations go, Axsome Therapeutics' Net Cash Flow slumped by 169.89% in 2021, and later surged by 217.42% in 2022.
  • Yearly analysis of 5 years shows Axsome Therapeutics' Net Cash Flow stood at -$36.1 million in 2020, then crashed by 169.89% to -$97.4 million in 2021, then skyrocketed by 217.42% to $114.4 million in 2022, then spiked by 62.06% to $185.4 million in 2023, then slumped by 138.22% to -$70.8 million in 2024.